A Study of Pasireotide in People With Prolactinoma
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.
Prolactin-Producing Pituitary Tumor
DRUG: Pasireotide|OTHER: SF-36 and HADS
biochemical response rate, response rate as defined by a normal serum prolactin concentration (\<18.0 ng/ml for a male and \< 29.0 ng/ml for a female, within 24 weeks of treatment
radiographic response, RECIST criteria, V1.1 (30% decrease in longest tumor diameter), within 24 weeks of treatment
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.